Posted by Michael Wonder on 24 Oct 2023
US Food and Drug Administration accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent
24 October 2023 - Potential to be the first and only self-administered flu vaccine.
AstraZeneca’s supplemental biologics license application for the approval of a self- or caregiver-administered option for FluMist Quadrivalent, a needle-free nasal spray, has been accepted for review by the US FDA.
